Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV)…
Best state economies in America in 2026
Maybe the U.S. economy has dodged a bullet. A little over a year ago around this time,…
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older…
Space race comes for pharma: Why drug development is heading to orbit
The highly anticipated SpaceX mega-IPO is part of a space frenzy that is moving beyond satellite connectivity, launch…
How Is Pfizer’s Stock Performance Compared to Other Healthcare Stocks?
With a market cap of $149.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, manufactures,…
Pfizer (PFE) earnings Q1 2026
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press |…
How Ireland became dependent on big pharma — and the risks ahead
In just 50 years, Ireland has become the world’s third largest exporter of pharmaceuticals, with medicines now making…
Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a…
FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
More drugs should be over-the-counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter”…
Pfizer execs talk Metsera obesity drug
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in…